Bavaro Mary F
Infectious Diseases Division, Naval Medical Center San Diego, 34800 Bob Wilson Drive, San Diego, CA 92134, USA.
Curr Gastroenterol Rep. 2009 Aug;11(4):301-6. doi: 10.1007/s11894-009-0044-0.
Infections with Escherichia coli O157:H7 have gained media attention in recent years because of cases associated with unusual sources (eg, produce and swimming pools). Although most adults recover without sequelae, children and the elderly are more likely to develop complications (eg, hemolytic uremic syndrome and death). The diagnosis typically has been made by culture; however, newer hand-held immunoassays and polymerase chain reaction technology have led to more rapid detection of this important pathogen in stools, food, and water. Treatment is largely supportive; nonetheless, new methods to neutralize or bind toxin, such as probiotics, monoclonal antibodies, and recombinant bacteria, are showing promise to treat patients infected with E. coli O157:H7. The role of antibiotics in relation to this condition remains unclear.
近年来,感染大肠杆菌O157:H7因与异常来源(如农产品和游泳池)相关的病例而受到媒体关注。虽然大多数成年人康复后无后遗症,但儿童和老年人更易出现并发症(如溶血性尿毒症综合征和死亡)。诊断通常通过培养进行;然而,更新的手持式免疫测定法和聚合酶链反应技术已能更快速地在粪便、食物和水中检测出这种重要病原体。治疗主要是支持性的;尽管如此,中和或结合毒素的新方法,如益生菌、单克隆抗体和重组细菌,在治疗感染大肠杆菌O157:H7的患者方面显示出前景。抗生素在这种情况下的作用仍不明确。